B. Evans

Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults.

M. Fons, D. Mehrotra, R. Mogg, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficacy and safety of elbasvir/grazoprevir in treatment‐naive Chinese adults with hepatitis C virus infection: A randomized trial

E. Asante-Appiah, R. Talwani, Fu-Sheng Wang, 2020, JGH open : an open access journal of gastroenterology and hepatology.

Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

A. Howe, E. Barr, E. Lawitz, 2017, Hepatology.

O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks

A. Howe, E. Barr, E. Lawitz, 2015 .

Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance

D. Gutsch, M. Robertson, P. Saddier, 2012, Human vaccines & immunotherapeutics.

Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C‐CORAL study

E. Asante-Appiah, R. Talwani, Fu-Sheng Wang, 2018, Journal of gastroenterology and hepatology.

Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial

R. Talwani, I. Sheen, J. George, 2017 .